Befloxatone

Befloxatone is a monoamine oxidase inhibitor (MAOI) that was developed by Sanofi-Aventis for the treatment of depression. It acts by inhibiting the enzyme monoamine oxidase A (MAO-A), which breaks down serotonin, norepinephrine, and dopamine in the brain. By inhibiting this enzyme, befloxatone increases the levels of these neurotransmitters, which can help to alleviate the symptoms of depression.

History[edit | edit source]

Befloxatone was first synthesized in the 1990s by Sanofi-Aventis, a French multinational pharmaceutical company. It was developed as a potential treatment for depression, with the aim of providing a safer and more tolerable alternative to older MAOIs, which have significant side effects and dietary restrictions.

Pharmacology[edit | edit source]

Befloxatone is a selective and reversible inhibitor of MAO-A, an enzyme that degrades serotonin, norepinephrine, and dopamine in the brain. By inhibiting this enzyme, befloxatone increases the levels of these neurotransmitters, which can help to alleviate the symptoms of depression.

Clinical trials[edit | edit source]

Befloxatone has undergone several clinical trials to assess its efficacy and safety in the treatment of depression. However, the development of the drug was discontinued in the late 1990s due to concerns about its side effect profile.

Side effects[edit | edit source]

Like other MAOIs, befloxatone can cause a range of side effects, including nausea, dizziness, and insomnia. It can also cause a potentially dangerous increase in blood pressure if taken with certain foods or medications.

See also[edit | edit source]

Befloxatone Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.